Eurobio Scientific announces the signing of a distribution agreement with Canhelp Genomics, a company specialized in molecular diagnostics for oncology.
Under this agreement, Eurobio Scientific expands distribution of the Canhelp-UCa and Canhelp-Origin tests to France, Germany, the United Kingdom, Austria, Switzerland, and the Benelux region. This builds on the existing partnership in Italy and strengthens the Company’s position in precision oncology.
Strengthening Precision Oncology with Clinically Actionable Genomic Testing
With this partnership, Eurobio Scientific expands its portfolio of molecular diagnostic assays addressing areas of high unmet clinical need, where conventional diagnostic approaches often reach their limits. Both tests provide clinically actionable insights that support more precise and individualized treatment strategies.
Importantly, the assays are designed for decentralized use, enabling testing to be performed closer to the patient and supporting faster clinical decision-making.
UCa Test in Urothelial Carcinoma: Non-Invasive Detection and Monitoring
The Canhelp-UCa test is a CE-IVD molecular diagnostic assay designed for the non-invasive detection and recurrence monitoring of urothelial carcinoma, which includes both the bladder and upper urinary tract. Using an eight-gene RNA signature from a simple urine sample, the test delivers highly accurate molecular insights without the need for invasive procedures.1,2
Urothelial carcinoma is characterized by high recurrence rates and a significant burden of surveillance, often requiring repeated cystoscopies that can be uncomfortable and stressful for patients.3 In this setting, the UCa test provides a powerful complementary approach by enabling reliable detection through a convenient, non-invasive sample.
By combining high sensitivity and specificity with ease of use, the test supports clinicians in both early detection in symptomatic patients and ongoing disease monitoring. This helps reduce diagnostic uncertainty and enables more confident, timely clinical decisions.
For patients, the key benefit lies in a simpler and less invasive testing experience, with the potential to reduce the frequency of burdensome procedures and improve overall quality of care.
Canhelp-Origin Test in Cancer of Unknown or Uncertain Primary: Identifying Tumor Origin to Guide Treatment
The Canhelp-Origin test is a CE-IVD molecular diagnostic assay developed for patients with cancer of unknown or uncertain primary, where the site of origin cannot be determined using standard diagnostic approaches. The test analyzes the expression of 90 genes from tumor tissue to generate a molecular profile, which is then compared against a reference database covering 21 tumor types to predict the most likely tissue of origin.4
Cancer of unknown or uncertain primary represents a clinically challenging entity, often leading to empirical treatment approaches and poor prognosis.5 By providing a data-driven prediction of tumor origin, the Canhelp-Origin test enables clinicians to move beyond empirical treatment approaches toward more targeted, site-specific therapies.6
For patients, this means a greater chance of receiving more appropriate and potentially more effective treatment, even in complex metastatic settings where conventional diagnostics fail to identify the primary tumor. By reducing diagnostic uncertainty, the test supports more confident clinical decision-making and a more personalized approach to cancer care.
Seamless Integration into Existing Laboratory Infrastructure
Both assays are based on standardized RT-qPCR technology and are compatible with established platforms, including the QuantStudio™ 5 Dx Real-Time PCR system – used for assays such as EndoPredict® and Prolaris® – as well as the Applied Biosystems™ 7500 Real-Time PCR system and other RT-qPCR instruments.
This platform compatibility facilitates implementation in laboratories already equipped with RT-qPCR infrastructure, particularly within Eurobio Scientific’s existing installed base. Once implemented, laboratories can integrate the assays into their workflows while leveraging Eurobio Scientific’s expertise in decentralized molecular diagnostics.
Expanding Clinical Impact Through Strategic Partnership
“We are delighted to partner with Canhelp Genomics to bring their advanced molecular diagnostic solutions to our markets,” said Denis Fortier, CEO of Eurobio Scientific. “These tests complement our existing oncology portfolio and support clinicians in making informed, precision-based treatment decisions.”
“The partnership with Eurobio Scientific is a defining moment in our mission to make precision oncology accessible to patients worldwide,” stated Dr. Qinghua Xu, CEO of Canhelp Genomics. “Eurobio Scientific’s proven expertise in molecular diagnostics commercialization and their extensive European network make them the ideal partner to bring our solutions to the clinicians and patients who need them most.”
References:
- Xu H, et al. Development and prospective validation of a multitarget urine RNA assay for noninvasive detection of urothelial carcinoma. iScience, 2025, 28(12).
- Zhang H, et al. Large-scale Prospective Validation Study of a Multiplex RNA Urine Test for Noninvasive Detection of Upper Tract Urothelial Carcinoma. Eur Urol Oncol. 2024, 7(6): 1384-1393.
- Maas, M, et al. Urine biomarkers in bladder cancer — current status and future perspectives. Nat Rev Urol. 2023, 20(10): 597–614.
- Sun W, et al. Clinical validation of a 90-gene expression test for tumor tissue of origin diagnosis: a large-scale multicenter study of 1417 patients. J Trans Med. 2022, 20(1): 114.
- Raghav K. Cancer of unknown primary site. NEJM. 2025, 392(20): 2035-2047.
- Liu X, et al. Site-specific therapy guided by a 90-gene expression assay versus empirical chemotherapy in patients with cancer of unknown primary (Fudan CUP-001): a randomised controlled trial. Lancet Oncol. 2024, 25(8): 1092-1102.
English (UK)